CEL-SCI Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CVM research report →
Companycel-sci.com
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
- CEO
- Geert R. Kersten
- IPO
- 1983
- Employees
- 43
- HQ
- Vienna, VA, US
Price Chart
Valuation
- Market Cap
- $10.93M
- P/E
- -0.57
- P/S
- 0.00
- P/B
- 1.88
- EV/EBITDA
- -0.96
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -221.50%
- ROIC
- -143.23%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-25,411,055 · 5.61%
- EPS
- $-6.27 · 53.56%
- Op Income
- $-24,809,736
- FCF YoY
- -90653.05%
Performance & Tape
- 52W High
- $13.48
- 52W Low
- $0.89
- 50D MA
- $3.13
- 200D MA
- $6.21
- Beta
- 0.71
- Avg Volume
- 315.65K
Get TickerSpark's AI analysis on CVM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | KERSTEN GEERT R | buy | 300,000 |
| May 13, 26 | KERSTEN GEERT R | buy | 100,000 |
| Mar 31, 26 | TALOR EYAL | other | 747 |
| Mar 31, 26 | PRICHEP PATRICIA B | other | 1,336 |
| Mar 31, 26 | KERSTEN GEERT R | other | 1,682 |
| Jan 22, 26 | KERSTEN GEERT R | buy | 38,023 |
| Dec 31, 25 | TALOR EYAL | other | 456 |
| Dec 31, 25 | PRICHEP PATRICIA B | other | 815 |
| Dec 31, 25 | KERSTEN GEERT R | other | 998 |
| Dec 4, 25 | KERSTEN GEERT R | buy | 8,389 |
Our CVM Coverage
We haven't published any research on CVM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CVM Report →